| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$11.9M | ROE | −260.11% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $5.8M | Trading Days | 879 |
| 52W High | 14.64 |
| 52W Low | 1.86 |
| % Off High | −86.27% |
| YTD | −70.35% | 1Y | −82.64% |
| 3Y | −84.36% | Since incept. (ann.) | −62.23% |
| Ann. Volatility (1Y) | 101.50% | Ann. Volatility (3Y) | 100.35% |
| Sharpe (1Y) | −1.24 | Sharpe (3Y) | −0.14 |
| Max Drawdown (1Y) | −85.85% | Max Drawdown (3Y) | −92.64% |
| Beta (3Y, vs SPY) | 2.02 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | $5.7M | — |
| CURX | Curanex Pharmaceuticals Inc | $5.6M | — |
| INM | InMed Pharmaceuticals Inc. | $5.5M | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $5.5M | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $6.1M | — |
| PULM | Pulmatrix, Inc. | $6.1M | — |
| LIANY | LianBio | $5.4M | — |
| SNGX | SOLIGENIX, INC. | $5.4M | — |
| GOVX | GeoVax Labs, Inc. | $5.4M | — |
| ALZN | Alzamend Neuro, Inc. | $6.3M | — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $6.3M |
| — |
| APVO | Aptevo Therapeutics Inc. | $5.2M | — |
